The diminished expression of LSS in tumor cells may facilitate tumor immunosuppression and progression via OS–PDL1 axis, thereby indicating that the level of OS or LSS could serve as a potential biomarker for the clinical use of PD1/PDL1 inhibitors (Figure 7F). This evidence concerns the gene CD274 and neoplasm.